WEBULL
WebtradeDownload

DSM-Firmenich (ENXTAM:DSFIR) Gains On Earnings Optimism As Valuation Comes Under Review

Simply Wall St · 2d ago

Recent upward earnings estimate revisions and a strong momentum ranking for DSM-Firmenich (ENXTAM:DSFIR) have put the stock in focus as investors reassess how this sentiment shift aligns with its current valuation.

That backdrop of rising earnings expectations comes after a strong run in the DSM-Firmenich share price, with a 1-month share price return of 16.57% and a 90-day move of 21.14%, while the 1-year total shareholder return of 48.61% and 3-year total shareholder return of 43.61% suggest momentum has been building rather than fading.

Compare DSM-Firmenich's momentum with other fast-moving opportunities by scanning our hand-picked list of 621 high quality undiscovered gems that are also catching fresh earnings optimism.

After a move like this, DSM-Firmenich is no longer an obvious under-the-radar play. The question now is whether the current valuation still leaves enough upside to justify the risk.

Most Popular Narrative: 8% Overvalued

Against the last close at €103.65, the most followed narrative pegs DSM-Firmenich's fair value at €95.87. This frames the recent share price surge as stretching slightly beyond that reference point while still hinging on strong execution in health and nutrition.

The rollout of innovative, health-focused ingredients (e.g., reduced sugar, salt, and enriched with healthy components) and strong demand for preventative health products positions DSM-Firmenich to benefit from growing consumer health and wellness trends. This supports sustained organic revenue growth in key segments like Taste, Texture & Health and Health, Nutrition & Care. Investment in fermentation and bio-based solutions (e.g., Amberever, algal lipids, HMOs), alongside the exit from lower-margin, less sustainable businesses, is expected to lead to higher product differentiation, pricing power, and margin expansion aligned with rising preferences for sustainable alternatives.

See why 30 investors see DSM-Firmenich as 8% overvalued.

Result: Fair Value of €95.87 (OVERVALUED)

Still, DSM-Firmenich’s story can change quickly if currency swings continue to reduce reported profits or if softer demand from larger global clients persists.

Find out about the key risks to this DSM-Firmenich narrative.

Another View: DSM-Firmenich Through A Cash Flow Lens

The popular narrative frames DSM-Firmenich as 8% overvalued at €103.65 compared with a €95.87 fair value anchored on analyst targets and multiples. Our DCF model tells a very different story. On that approach, the shares trade about 26% below an estimated cash flow value of €140.61. Which signal matters more to you: sentiment or cash generation potential?

To see how that cash flow result is built up over time, and how sensitive it is to the assumptions you agree with most, Look into how the SWS DCF model arrives at its fair value..

DSFIR Discounted Cash Flow as at Oct 2026
DSFIR Discounted Cash Flow as at Oct 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out DSM-Firmenich for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 185 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the split view on DSM-Firmenich leaves you unsure, act promptly, review the numbers yourself, and consider both sides with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond DSM-Firmenich?

Do not stop with DSM-Firmenich. Use the Simply Wall Street Screener to uncover fresh opportunities that match your risk tolerance, income needs, and balance sheet preferences.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.